Evaluation of Ciprofloxacin as a Representative of Veterinary Fluoroquinolones in Susceptibility Testing

Riddle, Christa; Lemons, Carol; Papich, Mark G.; Altier, Craig

doi:10.1128/jcm.38.4.1636-1637.2000

Cited by 34 publications

(33 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Interpretation of AUC 24 /MIC ratio after enrofloxacin administration is complicated by the existence of its primary active metabolite ciprofloxacin for which MIC values can be different compared with its parent compound (Riddle et al, 2000). In this study, ciprofloxacin accounted for 13.8% and 18.7% of the total fluoroquinolone (enrofloxacin + ciprofloxacin) AUCs after intra-venous and oral enrofloxacin administration, respectively, in agreement with published data (Papich et al, 2002).…”

Section: Enrofloxacin and Marbofloxacin In Horses 341supporting

confidence: 89%

Enrofloxacin and marbofloxacin in horses: comparison of pharmacokinetic parameters, use of urinary and metabolite data to estimate first‐pass effect and absorbed fraction

Peyrou

Bousquet‐mélou

Laroute

et al. 2006

Vet Pharm & Therapeutics

View full text Add to dashboard Cite

Enrofloxacin and marbofloxacin are two veterinary fluoroquinolones used to treat severe bacterial infections in horses. A repeated measures study has been designed to compare their pharmacokinetic parameters, to investigate their bioavailability and to estimate their absorbed fraction and first-pass effect by using plasma, urinary and metabolite data collected from five healthy mares. Clearance and V(d(ss)) were greater for enrofloxacin (mean +/- SD = 6.34 +/- 1.5 mL/min/kg and 2.32 +/- 0.32 L/kg, respectively) than for marbofloxacin (4.62 +/- 0.67 mL/min/kg and 1.6 +/- 0.25 L/kg, respectively). Variance of the AUC(0-inf) of marbofloxacin was lower than that for enrofloxacin, with, respectively, a CV = 15% and 26% intravenously and a CV = 31% and 55% after oral administration. Mean oral bioavailability was not significantly different between marbofloxacin (59%) and enrofloxacin (55%). The mean percentage of the dose eliminated unchanged in urine was significantly higher for marbofloxacin (39.7%) than that for enrofloxacin (3.4%). Absorbed fraction and first-pass effect were only determinable for enrofloxacin, whereas the percentage of the dose absorbed in the portal circulation was estimated to be 78% and the fraction not extracted during the first pass through the liver was 65%. Consequently, the moderate observed bioavailability of enrofloxacin appears to be mainly caused by hepatic first-pass effect.

show abstract

Section: Enrofloxacin and Marbofloxacin In Horses 341supporting

confidence: 89%

Enrofloxacin and marbofloxacin in horses: comparison of pharmacokinetic parameters, use of urinary and metabolite data to estimate first‐pass effect and absorbed fraction

Peyrou

Bousquet‐mélou

Laroute

et al. 2006

Vet Pharm & Therapeutics

View full text Add to dashboard Cite

show abstract

“…dose were in close agreement in this study but are among the shortest reported for any fluoroquinolone in birds (Flammer et al, 1991;Anadon et al, 1995;Helmick et al, 1997;Intorre et al, 1997;Bailey et al, 1998;Knoll et al, 1999;Harrenstien et al, 2000;de Lucas et al, 2004de Lucas et al, , 2005bCarpenter et al, 2006;Dimitrova et al, 2007). However, pharmacokinetic comparisons alone do not necessarily indicate advantages in efficacy or prevention of resistance, given the nonequivalency among fluoroquinolone MICs (Riddle et al, 2000). Effective use of concentration-dependent fluoroquinolones while preventing selection for resistance has been associated with reaching a daily maximum plasma concentration (C max ) 8-10 times the minimum inhibitory concentration for 90% of the population (MIC 90 ) of the pathogenic organism, rather than maintaining a concentration above MIC 90 (Papich & Riviere, 2009).…”

Section: Discussionsupporting

confidence: 84%

Pharmacokinetic–pharmacodynamic integration of orbifloxacin in Japanese quail (Coturnix japonica) following oral and intravenous administration

Hawkins

Taylor

Byrne

et al. 2010

Vet Pharm & Therapeutics

View full text Add to dashboard Cite

The pharmacokinetics of single-dose administration of orbifloxacin were determined in Japanese quail (Coturnix japonica) at dosages of 5 mg/kg intravenous (i.v. n = 12) and 7.5 mg/kg oral (p.o.; n = 5), 10 mg/kg p.o. (n = 5), 15 mg/kg p.o. (n = 12) and 20 mg/kg p.o. (n = 5) via HPLC. Orbifloxacin minimal inhibitory concentrations (MICs) against 22 microbial isolates from various bird species were performed to calculate pharmacodynamic surrogate markers. The concentration-time data were analyzed using a naïve pooled data (NPD) approach and compartmental and noncompartmental methods. Steady-state volume of distribution (Vd(ss)) and total body clearance (Cl) after i.v. administration were estimated to be 1.27 L/kg and 0.60 L/h·kg, respectively. Following 15 and 20 mg/kg p.o. dose, bioavailability was 102% and 117%, respectively. The harmonic mean of the corresponding terminal half-lives (T(1/2) λ(z) ) across all the dose groups was 1.71 h. The C(max) /MIC(90) and AUC(0∞24) /MIC(90) for the 15 and 20 mg/kg p.o. doses were ≥5.22 and ≥8.98, and ≥25.80 and ≥39.37 h, respectively. The results of this study suggest that 20 mg/kg orbifloxacin p.o. would be a rational daily dose to treat susceptible infections in Japanese quail not intended for food consumption. For more sensitive bacterial organisms, 15 mg/kg p.o. may also be effective.

show abstract

“…Ciprofloxacin, a fluoroquinolone registered for use in humans and available in generic formulations, is also administered to dogs and cats due to its greater activity against some isolates of Pseudomonas aeruginosa compared with other fluoroquinolones. 1 Newer or fourth generation fluoroquinolones such as moxifloxacin are also available to treat respiratory tract infections in humans because of their additional activity against anaerobic bacteria and improved efficacy against Gram positive organisms. 2 Pradofloxacin, which has a similar spectrum of activity and chemical composition to moxifloxacin, is presently undergoing registration for veterinary use.…”

Section: Atcc American Type Culture Collection E-testmentioning

confidence: 99%

Susceptibility of canine and feline Escherichia coli and canine Staphylococcus intermedius isolates to fluoroquinolones

et al. 2008

View full text Add to dashboard Cite

This is the first report comparing the MICs for all veterinary fluoroquinolones currently available in Australia for a representative sample of canine and feline E coli and canine S intermedius isolates. Importantly, this study identified 12 of 59 canine E coli isolates resistant to fluoroquinolones and identified the development of low level resistance in canine E coli to ciprofloxacin and enrofloxacin and canine S intermedius to amoxycillin-clavulanate.

show abstract

Evaluation of Ciprofloxacin as a Representative of Veterinary Fluoroquinolones in Susceptibility Testing

Cited by 34 publications

References 4 publications

Enrofloxacin and marbofloxacin in horses: comparison of pharmacokinetic parameters, use of urinary and metabolite data to estimate first‐pass effect and absorbed fraction

Enrofloxacin and marbofloxacin in horses: comparison of pharmacokinetic parameters, use of urinary and metabolite data to estimate first‐pass effect and absorbed fraction

Pharmacokinetic–pharmacodynamic integration of orbifloxacin in Japanese quail (Coturnix japonica) following oral and intravenous administration

Susceptibility of canine and feline Escherichia coli and canine Staphylococcus intermedius isolates to fluoroquinolones

Contact Info

Product

Resources

About